Table 1.
Demographic characteristics of the patients with PPLELC.
| Patient | Sex | Age (y) | Smoking status | Method of diagnosis | Site of tumor | Tumor size (cm) | TNM staging | Overall staging | Serum EBV examination | PD-L1 expression | EGFR | ALK | ROS-1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 58 | N | Operation | RLL | 5.1 | T3N2M0 | IIIA | unknown | 40% | Negative | Negative | Negative |
| 2 | Female | 53 | N | Operation | LUL | 2.3 | T1bN0M0 | IA2 | unknown | 30% | Negative | Negative | Negative |
| 3 | Female | 48 | N | EBUS bronchoscopy | RML | 4.7 | T2bN2M1 | IV | unknown | 90% | Negative | Negative | Negative |
| 4 | Female | 56 | N | CT-guided percutaneous needle lung biopsy | LLL | 6.4 | T4N2M1b | IV | EBV-EA-IgG positive | 80% | Negative | Negative | Negative |
| 5 | Female | 63 | N | Bronchoscope biopsy | RML | 7.0 | T4N3M1 | IV | EB-DNA 9.10E+03 copies/mL | 5% | Negative | Negative | Negative |
EBUS, endobronchial ultrasound; RLL, right lower lobe; LUL, left upper lobe; RML, right middle lobe; LLL, left lower lobe; EBV, Epstein-Barr virus; PD-L1, programmed cell death-1.